FUKOKU MUTUAL LIFE INSURANCE Co raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 57.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 203,143 shares of the companyâ€™s stock after buying an additional 74,000 shares during the quarter. Merck & Co., Inc. comprises about 1.8% of FUKOKU MUTUAL LIFE INSURANCE Coâ€™s investment portfolio, making the stock its 16th biggest position. FUKOKU MUTUAL LIFE INSURANCE Coâ€™s holdings in Merck & Co., Inc. were worth $12,331,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of MRK. Strategic Financial Services Inc raised its position in Merck & Co., Inc. by 1.0% in the second quarter. Strategic Financial Services Inc now owns 102,485 shares of the companyâ€™s stock valued at $6,221,000 after purchasing an additional 1,002 shares during the period. Signition LP purchased a new position in Merck & Co., Inc. in the second quarter valued at about $402,000. Cedar Hill Associates LLC raised its position in Merck & Co., Inc. by 64.3% in the second quarter. Cedar Hill Associates LLC now owns 6,121 shares of the companyâ€™s stock valued at $372,000 after purchasing an additional 2,395 shares during the period. Brighton Jones LLC raised its position in Merck & Co., Inc. by 9.6% in the second quarter. Brighton Jones LLC now owns 25,584 shares of the companyâ€™s stock valued at $1,553,000 after purchasing an additional 2,250 shares during the period. Finally, Blue Fin Capital Inc. raised its position in Merck & Co., Inc. by 4.7% in the second quarter. Blue Fin Capital Inc. now owns 30,415 shares of the companyâ€™s stock valued at $1,846,000 after purchasing an additional 1,357 shares during the period. 72.14% of the stock is currently owned by institutional investors.
Shares of MRK stock opened at $70.94 on Friday. The company has a market capitalization of $191.27 billion, a price-to-earnings ratio of 16.89, a P/E/G ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $71.57.Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating the Zacksâ€™ consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion for the quarter, compared to analystsâ€™ expectations of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The businessâ€™s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 earnings per share. analysts predict that Merck & Co., Inc. will post 4.27 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 5th. Stockholders of record on Monday, September 17th will be issued a dividend of $0.48 per share. The ex-dividend date of this dividend is Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.71%. Merck & Co., Inc.â€™s dividend payout ratio (DPR) is presently 48.24%.
MRK has been the topic of several research reports. TheStreet raised Merck & Co., Inc. from a â€śc+â€ť rating to a â€śb-â€ť rating in a research report on Friday, June 8th. Zacks Investment Research upgraded Merck & Co., Inc. from a â€śholdâ€ť rating to a â€śbuyâ€ť rating and set a $69.00 target price for the company in a research note on Thursday, June 7th. Morgan Stanley set a $74.00 target price on Merck & Co., Inc. and gave the company a â€śbuyâ€ť rating in a research note on Thursday, August 23rd. SunTrust Banks restated a â€śbuyâ€ť rating and set a $77.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, August 16th. Finally, Bank of America lifted their price target on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a â€śbuyâ€ť rating in a research note on Monday, July 30th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the companyâ€™s stock. The company currently has a consensus rating of â€śBuyâ€ť and an average target price of $68.55.
In related news, insider Sanat Chattopadhyay sold 29,208 shares of the businessâ€™s stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $65.20, for a total transaction of $1,904,361.60. Following the sale, the insider now owns 70,675 shares of the companyâ€™s stock, valued at $4,608,010. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Kenneth C. Frazier sold 279,851 shares of the businessâ€™s stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $70.08, for a total value of $19,611,958.08. Following the sale, the chairman now directly owns 971,801 shares in the company, valued at approximately $68,103,814.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 649,510 shares of company stock worth $44,201,809. Corporate insiders own 0.32% of the companyâ€™s stock.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Read More: Return on Equity (ROE)
Receive News & Ratings for Merck & Co. Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Co. Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.